Astellas has begun considering strategic options for the future of its UK R&D subsidiary Prosidion, which it acquired last year as part of the purchase of OSI Pharmaceuticals but now apparently considers surplus to its core interests.
The Japanese company has retained Citigroup Global Markets to review a range of alternatives to maximise shareholder returns from the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?